New Zealand markets open in 8 hours 21 minutes
  • NZX 50

    11,137.88
    -19.78 (-0.18%)
     
  • NZD/USD

    0.6357
    +0.0047 (+0.74%)
     
  • ALL ORDS

    7,350.60
    +24.40 (+0.33%)
     
  • OIL

    114.51
    +0.31 (+0.27%)
     
  • GOLD

    1,826.50
    +12.50 (+0.69%)
     

ReForm Biologics Changes Name to Comera Life Sciences

·2-min read

Leading biologics company aims to drive a compassionate new era of advanced, self-administered biologics through proprietary therapeutics and research collaborations

WOBURN, Mass., January 27, 2022--(BUSINESS WIRE)--ReForm Biologics, Inc., a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that the company has changed its name to Comera Life Sciences, Inc. The rebranding reflects a renewed focus to bring about a compassionate new era in medicine by applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms.

"We believe true medical advances are inspired by compassion and embrace this guiding philosophy at Comera," said Jeff Hackman, Chief Executive Officer, Comera Life Sciences. "Transforming the delivery of biologics has the potential to reduce healthcare costs and improve patient quality of life by reducing out-patient treatment times and offering patients self-injectable treatments that support greater independence."

To drive this transformative approach, Comera is applying its innovative formulation platform, SQore™, to develop a portfolio of proprietary SQ therapeutics with the goal of lowering healthcare costs, making it easier for patients to administer their medicines, and ultimately enhancing patients’ lives. Comera will also continue to collaborate with pharmaceutical and biotechnology companies, applying its SQore™ platform to partners’ biologic medicines to deliver enhanced formulations that facilitate self-injectable care.

"Our renewed focus is driven by two critical trends – that patient care is increasingly managed by patients and families themselves, who want the ability to access advanced biologic medicines on their terms, and the business reality that biologics represent the majority of new therapeutics," said Neal Muni, M.D., Chief Operating Officer, Comera Life Sciences. "We believe Comera is well-positioned to capitalize on these trends well into the future."

The Comera Life Sciences team includes compassionate pharmaceutical executives, patient-centric medical doctors, and industry-leading experts in pharmaceutical product development, colloid chemistry, and interfacial dynamics that complement its leadership in traditional protein chemistry. The company’s combined protein and small molecule capability leverages a mechanistic understanding of protein-protein and protein-solvent interactions to tailor excipient selection for specific formulation needs. This unique scientific foundation supports the SQore™ platform for formulation work.

To learn more about the Comera Life Sciences mission, as well as the proprietary SQore™ platform, visit www.comeralifesciences.com.

About Comera Life Sciences

Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicine from intravenous (IV) to subcutaneous (SQ) forms. This approach is designed to provide patients with the freedom of self-injectable care, removing institutional burdens and putting patients in the center of their treatment regimen.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220126006097/en/

Contacts

Sean Leous
ICR Westwicke
Sean.Leous@westwicke.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting